Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Earl, loving your enthusiasm, but in the interests of accuracy, mention of further payments from Astra Zeneca and Sanofi should be preceded by the words UP TO
It's dollars not £s
Add C4XD
AstraZeneca already paid £11m
£405m still in the pipeline
plus Sanofi £404m still to come
mcap £30m
has anyone seen yesterday
Not pump..... this is in the rns....
$810m payments lined up for C4XD from AstraZeneca and Sanofi
Read Rns
Good pump Earl 🤣 In fairness it shouldn’t need it and you shouldn’t have been getting in today sub 20p but it is what is
Current mcap 30m - .Cash £20m and net assets £6.5m and also sanofi milestone payment imminent
Plus if AZ don’t buy them out more partnershiips to come with majors ?
Of course we have.
Why are you here?
Https://twitter.com/EquityTrader888/status/1742877575146258755?t=4Lfj68O9-LCGk7FvvzzFEQ&s=19
has anyone seen this?
£810M payment lined up for C4XD
Are AstraZeneca crazy???
They paid $11m already
Why not buy on the open market so money goes back to AstraZeneca
Many missed this yesterday
look at another multi bagger coming from This
AstraZeneca paid $11m to #c4xd
Mcap only only £29m
$400m payment still to come
AstraZeneca could buy the whole company for £250m still saves them £150m😮
#c4xd
AstraZeneca involved
AstraZeneca to pay upto £400, this is insane amount for a£25m Mcap company
why not Astra Zeneca buy C4xd on the open market......
for £250m that's 10 bagger minimum
AstraZeneca triggers $11 million preclinical milestone payment to C4X Discoveryunder its NRF2 exclusive worldwide licence agreement worth up to $402 million
3 January 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that it has received a milestone payment of $11 million from AstraZeneca triggered by preclinical progress of C4XD's NRF2 Activator programme.
Under the terms of the licensing agreement announced in November 2022, C4XD received an initial $2 million upfront payment and is potentially entitled to receive up to $400 million in preclinical, clinical development and commercial milestones, and to tiered mid-single digit royalties on future sales.
The sp was higher four weeks ago before the crazy fall/shorting....
DoubleD on "x" just posted and I agree...
Huge milestone for #C4XD. SP has been dragged down by funding concerns and lack of progress but timescales are notoriously long in pharma. SP up 40% today & at £30m MCAP is really only valued at cash in hand. Astonishingly undervalued given the pipeline and commercial agreements
Just out
News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.
Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Cap analysts backed aim-listed C4X.
“We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note.
“Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.”
The deal included an initial upfront payment of US$2 million to C4X and consisted of a series of developmental and commercial milestones.
Under this, C4X’s NRF2 activator programme has been out-licensed to AstraZeneca with the goal of creating an oral therapy for inflammatory and respiratory diseases.
Shore Cap added that its model for C4X suggested fair value of 52p per share, marking a prospective 480% increase on Tuesday’s closing value of 8.7p.
“These agreements serve as strong validation of C4XD’s prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process,” the bank said.
Indeed, the market reacted positively to the news, with shares in C4X climbing 37% to 11.98p following the news on Wednesday morning.
Only problem with small free float is can work against you if sellers dominate on certain days and MMS will work over the SP as a result. Saw the same with CSFS when I was a a buyer sub 7p, SP struggled to move above 9p for a while but when it did get going it multi bagged. Expect the same here, especially as bother CSFS and c4XD have the same brokers in Shore Cap.
Shore Cap projecting 50p for CSFS, currently @24p from a low of 6p. Broker target for C4XD 55p from a recent low of @8p.
Over seventy percent of the issued shares capital is owned by institutional investors and directors. This speaks volumes to me. Very small free float means retail investors buying in could push this multiple times higher .
Great News, happy that I invested, when I did :)
Goodluck to those who had the faith :]
TAKING AIM: C4X's Astra deal shows value to investors - Shore Capital
C4XD latest milestone payment in its AstraZeneca partnership signals a "stellar start" to 2024, Shore Capital research analyst Sean Conroy
Saw these 43% up on this site *( D ) not showing as a riser on table , made me wonder if I did hold .
There is hope for my 80% losing positions .
This news must of been known to any big boys before today's RNS .
News today.
C4X receives USD11 million from AstraZeneca following NRF2 trials
C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.
The Manchester, England-based drug discovery company received USD11.0 million from the Cambridge, England-based pharmaceutical maker AstraZeneca.
The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November.
In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.
C4X Chief Executive Officer Clive Dix said: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation. We believe that our unique approach can deliver transformative oral therapies for patients suffering from immuno-inflammatory diseases. This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024."
Shares in C4X were up 12% at 10.00 pence each in London on Wednesday morning.
By Hugh Cameron, Alliance News reporter
Runway was already to Dec 24 and now extended to around Sept 2025, even without any further milestone payments or a sale of the non-core Malt-1 asset (both of which are expected).
Mcap now around 30m. Morphic whose only asset is in the same space as ONE of C4XD's (and looking inferior in phase 1 trials due to the worryingly high dose required) has a market cap of $1.44 billion.
This has been floating under the radar for far too long.
All (unwarranted) funding worries now pushed out to ridiculous time horizons and CD has already said that it's entirely possible that the company is now self financing. There's really no reason for this not to fly much higher after the initial wave of profit taking.
I know the company gives interviews on proactive so would expect one there at least.
The share needs to be promoted. Vox Markets might be a start as Vox has done wonders for the likes of Destiny Pharma. There's no point in being a success if hardly anyone knows about it. Come on Clive et al get out there and tell the market the great story and prospects to come.
The market potential in immuno-inflammation is large and growing, reflecting the need for better treatments. With a robust balance sheet, focused strategy and streamlined portfolio, we believe we are strongly positioned in immuno-inflammation and excited about the future.
On the out-licensed programme, the company noted that Sanofi is making progress on the IL-17A inhibitor programme for inflammatory diseases towards the next milestone.
Of its portfolio of early-stage discovery immuno-inflammatory molecules, the board still anticipates moving two projects into lead optimisation by the end of 2024, following the project initiation process assessment involving C4X’s proprietary platforms, Conformetrix and PatientSeek, together with a thorough analysis of the commercial viability.
PatientSeek was launched in February to optimise patient selection, with the potential to match the most effective treatments with groups of patients who are most likely to benefit thereby ensuring the right drug is given to the right patient, based on their genetics.
Only 12.8p to buy and a market cap of only 25 million with the potential to get 400 million dollars, well im in but am i missing something.
Neil is just another sad troll with nothing better to do. Suspect he may be posting as firestarter on advfn who does the same on any shares that issue good news and see material gains.